Australian Shares Fall as Westpac Slides, Miners Gain Ahead of RBA Decision 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
The ghost of Robodebt – Federal Court rules billions of dollars in welfare debts must be recalculated 
Gold Prices Rise as Fed Rate Hike Bets Ease 
What’s the difference between baking powder and baking soda? It’s subtle, but significant 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Why have so few atrocities ever been recognised as genocide? 
Disaster or digital spectacle? The dangers of using floods to create social media content 
Oncologica has launched its Prostatefocus cancer genetic screening test that identifies men at increased risk of developing prostate cancer.
A significant proportion of men, particularly those people who develop aggressive life-threatening prostate cancer at a relatively early age, can now be identified as a consequence that they carry inherited abnormal disease-causing genes.
The family of inherited prostate cancer-causing genes is all involved in a process called DNA damage repair (DDR) which plays a critical role in ensuring that the DNA in your cells is maintained in a healthy state.
An inherited abnormality in any of these DDR genes predisposes men to the development of early aggressive prostate cancer. Notably, survival among men with faulty DNA repair genes is half that of men with normal DDR genes.
The new genetic Prostatefocus genetic screening test uses a simple saliva self-sample collection kit. Men who test positive can then benefit from regular checks, blood tests, and lifestyle preventative measures.
Dr. Marco Loddo, co-owner and scientific director at Oncologica, a leading genetic cancer and viral testing laboratory based in Cambridge UK, said that prostate cancer tends to grow slowly without symptoms, so men often present late with an advanced incurable disease.
Prostate cancer is more treatable when caught early so screening tests can help identify an individual at high risk of developing the disease so regular checks can take place.
The Prostatefocus test is available via Oncologica’s nationwide specialist medical healthcare providers who conduct a pre-test consultation explaining how the test works and the implications of any results.
